The potency and safety of platelet-rich plasma and its therapy protocol for erectile dysfunction: A systematic review and meta-analysis of randomized controlled trials
Abstract
Abstract* Background Platelet-rich plasma (PRP) is a novel treatment for erectile dysfunction (ED) that is considered to be a cost-effective option. It has demonstrated positive outcomes and minimal adverse effects. By injecting PRP into the intracavernous tissue, it has the potential to promote angiogenesis and neuroregeneration, leading to a potential permanent improvement in erectile performance. The potency and safety as well as the variety of PRP administration protocols in the treatment of ED are the objectives of this paper. Method Using certain terms, a systematic search was done on three different databases: Science Directs, Scielo, and PubMed. Papers about PRP therapy for EDs within the last decade, be randomized controlled trials (RCTs), and be original studies with freely available full-text content were included in this study. This article omitted letters to the editor, reviews, and editorials regarding PRP and ED. Results Three RCT were included in this studies. The improvement is observed at one month, three months, and six months after the treatment, compared to the baseline. PRP group participants met the Minimal Clinically Important Difference (MCID) in the International Index of Erectile Function-Erectile Function (IIEF-EF) at a higher percentage than those in the placebo group at both one month and six months. Injection of PRP leads to a superior enhancement in the IIEF-EF score, compared to a placebo, in patients suffering from ED at one month, three…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.